Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NIH-supported study finds no serious complications following rare immune condition.
The number of pediatric inpatient units in hospitals fell 19% from 2008 to 2018.
After a long wait, the FDA authorizes Pfizer and Moderna vaccines for children as young as 6 months old.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
The current leading suspect is an adenovirus, but much more remains to be learned.
An NIH-funded study compared more than 1.1 million students across nine states.
Vaccines for children under age 5 are still not on the immediate horizon.
Earlier studies on safety measures in schools were often conducted in affluent and ethnically homogeneous neighborhoods.
NIH-supported research will track effects of coronavirus infection on children over three years.
Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.
MIS-C is a rare but life-threatening complication in which a hyperactive immune system attacks a child’s body.
The pending authorization of COVID-19 vaccines for children ages 5 to 11 is a light at the end of the quarantine tunnel.
Identifying and caring for these children is a necessary and urgent part of the pandemic response.
Studies highlight the importance of using layered prevention strategies to minimize disruptions to safe in-person education.
What protects most children from becoming seriously ill? And why does that protection sometimes fail?
As schools reopen, parents have questions about when COVID-19 vaccines will be available for children under 12.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.